[Asia Economy Reporter Geum Bo-ryeong] On the afternoon of the 23rd, Celltrion, Celltrion Pharm, and Celltrion Healthcare, which are scheduled to hold a press conference related to COVID-19 treatment and diagnostic kits, are showing strong performance despite the declining market.
As of 2:38 PM on the same day, Celltrion recorded 175,000 KRW, up 15.08% (23,000 KRW) compared to the previous day. At the same time, Celltrion Healthcare rose 8.01% (5,000 KRW) to 67,400 KRW, and Celltrion Pharm increased 26.39% (9,000 KRW) to 43,100 KRW.
Seojeongjin, Chairman of the Celltrion Group, is known to hold an online press conference after the market closes today regarding the "progress of COVID-19 antibody treatment and diagnostic kit development and the possible timing for human clinical trials."
Chairman Seo also announced plans at the first online press conference held on the 12th to develop a COVID-19 treatment within six months and a rapid diagnostic kit within three months, if possible.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
